

1 Exploring the neuroprotective effects of tibolone during astrocytic metabolic inflammation: a flux balance analysis approach

Written by: *Daniel Osorio, Janneth Gonzalez and Andrés Pinzón-Velasco.*

Abstract:

Inflammation is a complex biological response to injuries, metabolic disorders or infections and its dysregulation induce many complex diseases through astrocytic dysfunction. The increase of free saturated fatty acid produce a metabolic inflammation response, generally associated with the induction of diverse intracellular stresses, such as mitochondrial oxidative stress, endoplasmic reticulum stress, and autophagy defects. Astrocytes respond to inflammation through a complex reaction called astrogliosis. During astrogliosis, glial cells generally associated to several beneficial activities in the CNS, also act as a source of inflammatory mediators and as generators of ROS that have the potential to damage neurons. In search of compounds with neuroprotective effects that imitate the neuroprotective actions of esterooids without their perjudicial side effects; the syntetic neurosteroid Tibolone was identified. Tibolone acts as a estrogen receptor modulator (SERM), a selective tissue estrogenic activity regulator (STEAR) and has been shown neuroprotective effects in cultured and under ischemia injury rat neurons. Nevertheless, actually is not well know the effects of tibolone over glial cells that allows its neuroprotective action. In this work, we model and simulate the metabolic inflammation response in mature astrocytes through Flux Balance Analysis (FBA), and explore the neuroprotective effects of tibolone under the inflamed state. We focused in identification of changes in metabolic pathways activation, functional products, gliotransmitter release and the neuroprotective effects mediated by tibolone over inflamed scenario. The generated network, consisted of 1262 genes encoding for enzymes performing 2747 reactions distributed across eight compartments, which was studied using constrained-based modeling approach to recreate three different scenarios in mature astrocytes (healthy, inflamed and medicated), and validated with available experimental

evidences. From our analysis, we predict that

1.1. Introduction

Astrocyte-Neuron Metabolic Relationships

Astrocytes are the most abundant cells in the human brain and play important roles in the central nervous system (CNS) [1]. They are highly associated to several homeostatic functions such as glutamate, ion, and water homeostasis, energy storage in the form of glycogen, synapse formation and remodeling, defense against oxidative stress, scar formation, tissue repair and modulation of synaptic activity via the release of gliotransmitters [2]. Astrocytes metabolize glucose in anaerobic way to produce lactate, which is released to neurons through monocarboxylate transporters [3]. Lactate is used in neurons as an energy substrate after its conversion to pyruvate and subsequently to ATP via oxidative phosphorylation [4]. Astrocytes play an important role in glutamate mediated synaptic activity [5]; according to the astrocyte–neuron lactate shuttle model, astrocytes respond to glutamate induced activation by increasing their rate of glucose uptake and the release of lactate into the extracellular space, increasing the lactate available to be used by neurons to supply their energetic needs [6]. Glutamate is uptaked by astrocytes through the glutamate aspartate transporter and glial glutamate transporter-1, inducing events that involves the activation of $\text{Na}^+\text{--K}^+\text{--ATPase}$ and maintaining extracellular glutamate at homeostatic levels [7]. Part of incorporated glutamate is converted to glutamine through glutamine synthetase, which is only associated to glial cells and released to neurons using electroneutral systems-N transporters coupled to Na^+ and H^+ [8]. In neurons glutaminase enzyme converts glutamine back into glutamate which can be used again for neurotransmission or metabolized into the neuronal Krebs cycle [9]. Astrocytes release many other substances related to synaptic transmission [10]. However D-serine, a neurotransmitter that act as a coagonist with glutamate at NMDA receptors is one of the most important [5]. Due in brain only glial cells can synthesize serine, all available D-serine at synapsis is associated to be primarily produced and secreted by astrocytes [8]. D-serine is synthesized in astrocytes by serine racemase from L-serine [11]. Serine and glycine are involved in a cycle between astrocytes and neurons sim to the glutamate-glutamine cycle [56]. Additionally to these energy and synaptic support associated functions, astrocytes also play an important role in the reduced glutathione (GSH) metabolism of the brain [12]. GSH is the major cellular antioxidant and plays an important neuroprotective role [13]. Cellular GSH levels are closely correlated with cell survival under adverse conditions [14]; it is synthesized from glutamate, cysteine, and glycine and release directly from astrocytes through GSH transporters ion-independent and its net transport is concentration-gradient dependent [15]. This strong metabolic cooperation between astrocytes and neurons allows to predict that even an small astrocytic dysfunction might cause and/or contribute neurodegenerative processes [16]. Homeostatic astrocyte function is required for neuronal survival after

different brain insults, such as inflammation, glucose deprivation, traumatic brain injury and ischemia [13, 17]. Astrocytes protect neurons of the most important factors that contribute to neuronal cell death such as glutamate-mediated excitotoxicity leading to disturbances in calcium and sodium intracellular metabolism, mitochondrial dysfunction, oxidative stress, cytokines and toxins [1, 2, 7, 18].

Astrocytes response to Inflammation

Inflammation is a complex biological response to injuries, metabolic disorders or infections and its dysregulation induce many complex diseases through astrocytic dysfunction [13, 19, 20]. In brain, inflammatory response acts as a defense mechanism against any threat to homeostatic state inducing changes in glucose metabolism and release of proinflammatory factors [14]. Inflammation responses in CNS are mediated by glial cells that acquire reactive phenotypes to participate in repair mechanisms [1, 13, 21]. Astrocytes, as glial cells are highly sensitive cells to inflammatory mediators, they respond to inflammation through a complex reaction named astrogliosis [22]. During astrogliosis, glial cells generally associated to several beneficial activities in the CNS, also act as a source of inflammatory mediators and as generators of reactive oxidant species (ROS) that have the potential to damage neurons [23]. Astrogliosis is characterized by a low regulation of mitochondrial dynamics that result in mitochondrial failure [24]. Mitochondrial failure induces the deregulation of Ca^{2+} homeostasis and increased ROS generation, both of which are linked to neurotoxicity [2]. At metabolic level, inflammatory process has been associated to an increase of free saturated fatty acid in comparison with healthy conditions in some brain tissues [25]. The increase of free saturated fatty acid induce metabolic inflammation, a response associated with the induction of diverse intracellular stresses, such as mitochondrial oxidative stress, endoplasmic reticulum stress, and autophagy defects [13]. Lipid excess in metabolic inflammation activates $\text{IKK}\beta$ and $\text{NF-}\kappa\beta$ signaling pathways, which ultimately impairs leptin and insulin hormonal signaling and further triggers the synthesis and release of increased amounts of ROS and proinflammatory cytokines ($\text{TNF-}\alpha$ and IL-6) from glial cells to sustain the neuroinflammatory state [26]. Enhanced ROS generation by reactive glial cells trigger mitochondria dysfunction in neuron, which induces neuronal apoptosis, the prerequisite for a diverse number of neurodegenerative conditions [27].

Systems Biology and Inflammation

Inflammatory pathways are evolutionarily conserved, complex, redundant and interconnected [28]. These characteristics difficult each attempt to understand any disease having inflammation at its core using the traditional reductionism-based scientific method and the current regulatory framework [29]. Traditional methods generally focus on single molecules and genes as the targets of study and potential therapy development, nevertheless mechanistic simu-

lation through a translational systems biology methods allows lead to an understanding of the origin of patterns based in omic data integration in order to facilitate the design of novel therapies [30]. Inflammation is a complex system, which is characterized by sensitivity to initial conditions, positive and negative feedback loops, combined robustness and fragility, and emergence of nonintuitive behaviors [31]. Translational Systems Biology to inflammation is focused on simulated clinical trials, trying to progress toward personalized diagnostics, personalized medicine, and the rational design of drugs [28].

Tibolone

Drugs as steroids compounds are the most potent and effective agents in controlling chronic inflammatory diseases [32]. However, steroids prescription is limited due their adverse side effects [33]. Some steroids synthesized in the nervous system, called ‘neurosteroids’, display beneficial neuroprotective properties, which may be of particular importance in the treatment of diseases where inflammation and neurodegeneration is predominant including age-dependent dementia, stroke, epilepsy, spinal cord injury, Alzheimer’s disease (AD) and Parkinson’s disease (PD) [34]. Neuroprotective actions of molecules that may imitate the neuroprotective actions of esterooids without the perjudicial side effects, such as selective estrogen receptor modulators (SERMs) and selective tissue estrogenic activity regulators (STEARs) have been tested in previous studies [35, 36]. Tibolone is one of these compounds with SERMs and STEARs activities, traditionally used as hormone replacement therapy in post-menopausal women [37]. Tibolone has been shown neuroprotective effects in cultured and under ischemia injury rat neurons [38]. Tibolone is a synthetic steroid drug with estrogenic, progestogenic, and weak androgenic actions; is metabolized in three compounds, two major active metabolites, 3α -hydroxytibolone and 3β -hydroxytibolone acting as potent agonists of the estrogen receptor (ER) and its metabolite $\Delta 4$ tibolone acting as agonists of the progesterone and androgen receptors [39]. Tibolone and their metabolites have tissue selective action mechanisms (progestogenic, androgenic and estrogenic) reported in liver, bone, breast and brain according to receptor interaction and activation [35]. Nevertheless, actually is not well know the effects of tibolone over glial cells that allows its neuroprotective action [17]. Previous studies have shown that 3-hydroxy-metabolites of tibolone exert agonistic actions on human astrocytes through the activation of estrogen receptors, indicating that astrocytes are a target for tibolone [38].

In this work we simulate the metabolic inflammatory response in mature astrocytes caused by the increase uptake of palmitate, the most common free saturated fatty acid. We model and simulate the metabolic response using a translational system biology approach called Flux Balance Analysis (FBA) described in methods. We focused in identification of changes in metabolic pathways activation, functional products, gliotransmitter release and the neuroprotective effects mediated by tibolone in the inflamed scenario.

1.2. Material and Methods

Tissue Specific Model Construction

The tissue specific model construction process started with the identification of all enzyme-coding genes expressed over the mean in at least 50 % of samples for healthy human astrocytes indexed in the GEO database [40] as GSE73721 [41]. Gene identifiers conversion from GeneCards[42] to ENTREZ [43] was performed through ‘UniProt.ws’ R Package [44]. Reactions associated with the identified genes were mapped from the Human Genome Scale Metabolic Reconstruction RECON 2.04 downloaded from the VMH Lab (<https://vmh.uni.lu>) [45]. The R package ‘g2f’ [46] was used to identify and fill the gaps using all no gene associated reactions included in RECON 2.04, as well as to identify and remove all blocked reactions from the reconstruction. All reactions involved in the conversion of extracellular glutamate, glycine, cysteine and glucose to extracellular glutamine, glycine, serine-D, reduced glutathione, lactate and ATP respectively were added. Exchange reactions were limited to components of the Dulbecco’s Modified Eagle Medium (DMEM) as input and gliotransmitters (glutamine, D-serine, ATP, glutamate), reduced glutathione, lactate, glucose, nitric oxide, prostaglandins and leukotrienes as output. Finally, syntax, mass-charge validation and creation of SBML files were carried out through the ‘minval’ R Package [47]. Reaction limits (upper and lower bounds) were constrained proportional to the mean gene expression reported for genes included in Gene-Protein-Reaction (GPR) [48] associated to each reaction in samples of 47 to 63 years old using ‘exp2flux’ R package [49]. All analysis were done by the ‘sybil’ [50] R Package running under R 3.3.1 [51].

Flux Balance Analysis

Flux Balance Analysis (FBA) is a linear optimization method for simulating metabolism that allows to identify the set of reactions involved in the production of a biological response within a metabolic model [52]. The metabolic reactions are represented internally as a stoichiometric matrix (S), of size $m * n$, where m represents the compounds and n the reactions; the entries in the matrix are the stoichiometric coefficients of the metabolites participating in a reaction [53]. The flux through all of the reactions in a network is represented by the vector v , which has a length of n . The concentrations of all metabolites are represented by the vector x , with length m . The systems of mass balance equations at steady state, $\frac{d_x}{d_t} = 0$ or $S * v = 0$. FBA seeks to maximize or minimize an objective function which can be any linear combination fluxes, to obtain a flux for each reaction, indicating how much each reaction contributes to the objective function [52]. FBA for healthy, inflamed and medicated scenarios was resolved using GLPK 4.60, setting the generic human biomass reaction included in RECON 2.04 and each one of reactions described in table 1-1 as objective functions. Models were analyzed by comparing fluxes between scenarios, metabolites production rate and sensitivity

analysis.

Table 1-1: Main metabolic capabilities associated to astrocytes represented as the set of objective functions used to evaluate neuroprotective effects of Tibolone under inflamed scenarios

ID	FORMULA REACTION	DESCRIPTION
Glu2Gln	1 glu_L[e] \Rightarrow 1 gln_L[e]	Glutamate - Glutamine Cycle
Gly2SerD	1 gly[e] \Rightarrow 1 ser_D[e]	Glycine to D-serine conversion
Glc2Lac	1 glc_D[e] \Rightarrow 2 lac_L[e]	Lactate production from Glucose
Glc2ATP	1 glc_D[e] \Rightarrow 36 atp[e]	ATP production from Glucose
Cys2GTHRD	1 cys_L[e] + 1 glu_L[c] + 1 gly[c] \Rightarrow 1 gthrd[e]	Catch of Cysteine to produce reduced Glutathione

Metabolic Scenarios

To test neuroprotective effects of tibolone during astrocytic metabolic inflammation we define three different metabolic scenarios. A ‘healthy’ scenario, where palmitate uptake rate was freely set by optimizer; an ‘inflamed’ scenario, where uptake rate of palmitate was forced to be stable in the mean of the half maximal inhibitory concentration (IC50) value for all objective functions included in table 1-1. IC50 values were calculated through a robustness analysis performed using uptake of palmitate (‘EX_hdca(e)’ in RECON 2.04) as control reaction and a 1000 points in the range from 0 to 1 mMgDW⁻¹h⁻¹ for each objective function. Uptake value where each objective function reached IC50 was selected and subsequently averaged. Finally, a medicated scenario, defined as an inflamed scenario that include 279 reactions associated with tibolone and estradiol-derived compounds metabolism. Ten specific reactions described in table 1-2 associated to specific Tibolone action mechanism non included in RECON 2.04 were added to medicated scenario.

Metabolic Changes

Metabolic changes across metabolic scenarios were measured through two different approximations. Flux differences for each reaction between optimized scenarios were measured using the fold change calculated as described in equation 1-1.

$$foldChange = \frac{valueModel2 - valueModel1}{|valueModel1|} \quad (1-1)$$

Table 1-2: Set of reactions associated to tibolone specific action mechanism in brain reported by Kloosterboer, H. J. (2004) added to medicated scenario model.

ID	FORMULA REACTION	DESCRIPTION
T1	tibolone[e] \Leftrightarrow	Tibolone exchange reaction
T2	tibolone[e] \Leftrightarrow a3OHTibolone[e]	3 α hydroxytibolone interconversion
T3	tibolone[e] \Leftrightarrow b3OHTibolone[e]	3 β hydroxytibolone interconversion
T4	tibolone[e] \Rightarrow d4tibolone[e]	Δ^4 tibolone isomer formation
T5	b3OHTibolone[e] \Rightarrow d4tibolone[e]	Δ^4 tibolone isomer formation from 3 β -hydroxytibolone
T6	a3OHTibolone[e] \Rightarrow estradiol[c]	Estradiol receptor agonist action mechanism of 3 α -hydroxytibolone
T7	b3OHTibolone[e] \Rightarrow estradiol[c]	Estradiol receptor agonist action mechanism of 3 β -hydroxytibolone
T8	d4tibolone[e] \Rightarrow prgstrn[c] + tststerone[c]	Progesterone and androgen receptor activation by tibolone Δ^4 isomer
T9	a3OHTibolone[e] \Leftrightarrow a3SOTibolone[e]	3 α hydroxytibolone interconversion to sulfated inactive compounds
T10	a3SOTibolone[e] \Rightarrow	Tibolone inactive form in blood

Additionally, to obtain a full perspective about inflammation effects in metabolites production, the production of each metabolite was set as objective function in each metabolic scenario and differences were evaluated as well as flux differences.

Proinflammatory, Antiinflammatory and Tibolone Action Mechanism Associated Enzymes

Identification of enzymes involved in proinflammatory and antiinflammatory responses as well as in the tibolone action mechanism were identified through several sensitivity analysis as follows: Proinflammatory enzymes, are those that catalyze reactions that being knocked out allows an increase of objective function value. Antiinflammatory enzymes, are those associated to reactions that have a fold-change greatest equal to 2 which at being knocked out reduce even more the objective function value. Tibolone action mechanism associated enzymes are those that catalyze reactions that being knocked out inhibit entirely the metabolic effect of tibolone.

1.3. Results

Tissue Specific Metabolic Model

Generated astrocyte tissue-specific model describe the metabolism of 1956 compounds in a total of 2747 biochemical reactions associated to 1262 unique genes. Biochemical reactions include 60 exchange and 1080 transport reactions (79% gene associated, facilitated or active transport) as is shown in figure 1-1A.




Figure 1-1: Reaction Classification based in **A:** Type, **B:** Catalytic Activity Required and **C:** Distribution by Compartment

To describe the astrocyte tissue specific metabolic model, reactions were classified on the basis of required enzymatic activity to be catalyzed according to their Enzyme Commission (E.C) numbers (Fig. 1-1B), sub-cellular locations according to metabolites compartment (Fig. 1-1C), and metabolic pathways assigned in the KEGG database (Fig. 1-2). Based in the associated enzyme to each biochemical reaction 33.2% of them are catalyzed by a transferase enzyme, 15.8% by an oxidoreductase, 14.4% by a hydrolase, 6.2% by a lyase, 2.3% by a ligase, 1.9% by an isomerase enzyme and 25.3% of them are spontaneous reactions without enzyme or gene associated. In the classification shown in Fig. 1-1C, the cytosolic and mitochondrial reactions contributed to 60% of the total reactions in the model. The other 40% of reactions are distributed in six other compartments as follows: 8.7% occurs in golgi apparatus, 8.5% in peroxisome, 6.9% in the endoplasmic reticulum, 6.3% in the lysosome, 4.2% in nucleus, finally 5.5% of them occurs outside the cell, in the extracellular space. Reactions included in astrocyte model are associated to 113 metabolic pathways reported in the KEGG database. Almost 50% reactions are associated to 10 main metabolic pathways, highly related to astrocytes metabolism and neuron support metabolic functions [6, 54–58]. Entirely distribution of reactions in metabolic pathways is shown in figure 1-2.




Figure 1-2: Pathways associated to biochemical reactions included in the astrocyte tissue-specific metabolic model. Pathway association was assigned based in the categorization of the KEGG database.

Healthy Scenario

As previously reported by a wet lab, healthy human astrocytes grow up in DMEM culture medium [59]. Our metabolic simulation allow to predict an astrocytes slow grow rate ($0.37 \text{ mMgWD}^{-1}\text{h}^{-1}$) under DMEM medium. In our healthy scenario (shown in figure 1-3), astrocytes activates the 52 % of model reactions and prefer a glucose based metabolism. Glucose is catabolized and constitutively released as lactate without any stimuli [60]. This observation is highly expected due astrocytes release large amounts of lactate in the extracellular space which can be used by neurons to supply their energy needs [14]. In our simulations, other gliotransmitters are synthetized and released by astrocytes only under specific stimulus (objective functions) and their release rate was used as reference to comparison between scenarios (Fig. 1-7).




Figure 1-3: Comparative exchange rate of metabolites between metabolic scenarios using the generic biomass reaction included in RECON 2.04 as objective function.

Inflamed Scenario

In the model, the healthy scenario was perturbed to generate the inflamed scenario. The palmitate induced IC₅₀ value calculated for a set of metabolic functions (described in table 1-1) was $0.208 \pm 0.024 \text{ mMgDW}^{-1}\text{h}^{-1}$. Calculated IC₅₀ value is the same (0.2 mM) used by Liu *et al.* in wet lab to induce an astrogliosis reaction [61]. Inflamed scenario increases the demand of L-asparagine, L-aspartate, iron, glucose, glutamate, histidine, L-serine and the release of glutamine and lactate (shown in figure 1-3). These response is typical of astrocytes in astrogliosis where neuroinflammation lead homeostatic disturbances [62], such




Figure 1-4: Robutness analysis to calculate palmitate induced IC50 value for each objective function described in table 1-1. Red line represents the calculated IC50 value.

as iron accumulation, within CNS cells [13]. Iron accumulation has been demonstrated in several neurodegenerative diseases as AD, and PD, where it has been postulated to promote disease by augmenting microglial proinflammatory activity, altering mitochondrial function, and inducing ROS production [63]. Inflammation although induce neuronal release of glutamate that may result in the recruitment of neurons in the neuroinflammatory process [64]. Glutamate uptake into astrocytes disinhibits glycolytic enzymes that results in glucose uptake; this glucose is generally processed glycolytically, leading to the synthesis and release of lactate [13]. As neurons cannot generate glutamine from glutamate owing to the lack of the glutamine synthetase enzyme, uptaken glutamate is returned to neurons via synaptic clefts in the form of glutamine [65]. Histidine uptake increase was previously reported and suggested as a biomarker of metabolic inflammation [66]; it acts as a free-radicals scavenger and could reduce the levels of IL-6, TNF- α , CRP and inhibit the H₂O₂⁻ and TNF- α induced by IL-8 secretion [67, 68]. Aspartate, present in brain as N-Acetyl-L-aspartate (NAA) is synthesized and stored in the neurons but is hydrolyzed in glial cells [69]. NAA act as an anti-proliferation, anti-angiogenic, and anti-inflammatory molecule through the decrease of the amount of prostaglandin E2 (PGE2) in astroglial cells [70]. L-Asparagine in turn acts

as a regulator of ammonia toxicity through a signalling cascade increasing intracellular Na^+ when is cotransported inside astrocytes (23) Asparagine induce a Ca^{2+} response comparable to GABA-induced Ca^{2+} transients in a dose-dependent manner.




Figure 1-5: Metabolic pathways affected by inflammation. Activation and inactivation percentage was measured in comparison with genes associated to each pathway in the KEGG database.

In our inflamed scenario, astrocytes activates the 46.6 % of model (5.6 % less than healthy scenario) and affect the biomass flux rate of 586 reactions in comparison with healthy scenario. Main metabolic changes occurs in the activation of oxidative phosphorylation, histidine metabolism and fatty acid degradation pathways; as well as an inactivation of TCA and glycolysis pathways (shown in figure 1-5). Inflammation affects in a negative way all metabolic objective functions evaluated except the release of D-serine. Growth over DMEM medium decrease in a 15.6 %, the catch of cysteine to produce reduced glutathione in a 59.3 %, conversion of glucose to ATP in a 72 %, and to lactate in a 74.4 %; finally, conversion of extracellular glutamate in glutamine reduces in a 67.7 % in comparison to the healthy scenario.

Sensibility analysis allows us to identify two candidate proinflammatory reactions, Formimidoyltransferase cyclodeaminase (FTCD), on the other hand, is significantly upregulated

Table 1-3: A simple longtable example

ID	REACTION DESCRIPTION	H. FLUX	I. FLUX	FOLD CHANGE
AKGMALtm	α -ketoglutarate/malate transporter	-0.17	-1.3	-6.85
NADH2_u10m	NADH dehydrogenase mitochondrial	0.12	0.37	2.17
r0639	Lauroyl-CoA: acetyl-CoA C-acyltransferase.	0.02	0.09	4.04
r0653	cMyristoyl-CoA: acetyl-CoA C-myristoyl transferase	0.02	0.09	4.04
r0714	(S)-3-Hydroxyhexadecanoyl-CoA: NAD ⁺ oxidoreductase	0.02	0.09	4.04
r0716	(S)-3-Hydroxyhexadecanoyl-CoA hydrolyase	0.02	0.09	4.04
r0718	(S)-3-Hydroxytetradecanoyl-CoA: NAD ⁺ oxidoreductase	0.02	0.09	4.04
r0720	(S)-3-Hydroxytetradecanoyl-CoA hydrolyase	0.02	0.09	4.04

Table 1-4: Proinflammatory reactions identified through a sensibility analysis.

ID	REACTION DESCRIPTION	H. FLUX	I. FLUX	FOLD CHANGE
FTCD	Formimidoyltransferase cyclodeaminase	0.39	1.28	2.28
H2Otm	H2O transport mitochondrial	-0.26	2.44	10.44

and functions to contribute with one-carbon units from histidine degradation to the folate pool.(10.1016/j.celrep.2015.04.010)

Medicated Scenario

1.4. Conclusion




Figure 1-6: •

Table 1-5: Tibolone associated reactions identified through a sensibility analysis.

ID	REACTION DESCRIPTION	GENES
r0739	Alcohol Dehydrogenase	ADH4, ADH5, ADH7
r2518	ATP-binding Cassette (ABC)	ABCD3
RE1804M	Cholestanetriol 26-monooxygenase	CYP27A1
RE1807M	Cholestanetriol 26-monooxygenase	CYP27A1




Figure 1-7:

Bibliography

- [1] Kazuhiro Takuma, Akemichi Baba, and Toshio Matsuda. Astrocyte apoptosis: Implications for neuroprotection. *Progress in Neurobiology*, 72:111–127, 2004.
- [2] Sofie C. Lange, Lasse K. Bak, Helle S. Waagepetersen, Arne Schousboe, and Michael D. Norenberg. Primary cultures of astrocytes: Their value in understanding astrocytes in health and disease. *Neurochemical Research*, 37:2569–2588, 2012.
- [3] Harold K Kimelberg. Functions of Mature Mammalian Astrocytes: A Current View. *The Neuroscientist*, 16(1):79–106, feb 2010.
- [4] Nicola J Allen and Ben Barres. Neuroscience: Glia - more than just brain glue. *Nature*, 457(7230):675–677, 2009.
- [5] Michael M Halassa and Philip G Haydon. Integrated brain circuits: astrocytic networks modulate neuronal activity and behavior. *Annual review of physiology*, 72(2):335–355, 2010.
- [6] Christian Giaume, Annette Koulakoff, Lisa Roux, David Holcman, and Nathalie Rouach. Astroglial networks: a step further in neuroglial and gliovascular interactions. *Nature reviews. Neuroscience*, 11(fEbRuARy):87–99, 2010.
- [7] Cora H. Nijboer, Cobi J. Heijnen, Vincent Degos, Hanneke L M Willemsen, Pierre Gressens, and Annemieke Kavelaars. Astrocyte GRK2 as a novel regulator of glutamate transport and brain damage. *Neurobiology of Disease*, 54:206–215, 2013.
- [8] Ben Barres. The mystery and magic of glia: a perspective on their roles in health and disease. *Neuron*, 60(3):430–40, nov 2008.
- [9] Jun Shen. Modeling the glutamate-glutamine neurotransmitter cycle. *Frontiers in Neuroenergetics*, 5(JAN):1–13, 2013.
- [10] Francesco Petrelli and Paola Bezzi. Novel insights into gliotransmitters. *Current Opinion in Pharmacology*, 26(Table 1):138–145, 2016.
- [11] Andrea R Durrant and Uriel Heresco-Levy. D-Serine in Neuropsychiatric Disorders: New Advances. *Advances in Psychiatry*, 2014:1–16, 2014.

- [12] Stephen P. Raps, James C K Lai, Leif Hertz, and Arthur J L Cooper. Glutathione is present in high concentrations in cultured astrocytes but not in cultured neurons. *Brain Research*, 493(2):398–401, 1989.
- [13] Mithilesh Kumar Jha, Dong Ho Park, Hyun Kook, In-Kyu Lee, Won-Ha Lee, and Kyoungso Suk. Metabolic Control of Glia-Mediated Neuroinflammation. *Current Alzheimer research*, 13(4):387–402, 2016.
- [14] Igor Allaman, Mireille Bélanger, and Pierre J. Magistretti. Astrocyte–neuron metabolic relationships: for better and for worse. *Trends in Neurosciences*, 34(2):76–87, feb 2011.
- [15] Xue Feng Wang and Max S. Cynader. Astrocytes provide cysteine to neurons by releasing glutathione. *Journal of Neurochemistry*, 74(4):1434–1442, 2000.
- [16] Nicholas J Maragakis and Jeffrey D Rothstein. Mechanisms of Disease: astrocytes in neurodegenerative disease. *Nature clinical practice. Neurology*, 2(12):679–689, 2006.
- [17] Marco Avila-Rodriguez, Luis Miguel Garcia-Segura, Ricardo Cabezas, Daniel Torrente, Francisco Capani, Janneth Gonzalez, and George E. Barreto. Tibolone protects T98G cells from glucose deprivation. *The Journal of Steroid Biochemistry and Molecular Biology*, 144(8):294–303, 2014.
- [18] Ghulam Hussain, Florent Schmitt, Jean-Philippe Loeffler, and Jose-Luis Gonzalez de Aguilar. Fattening the brain: a brief of recent research. *Frontiers in cellular neuroscience*, 7(September):144, 2013.
- [19] Brent E Masel and Douglas S DeWitt. Traumatic brain injury: a disease process, not an event. *Journal of neurotrauma*, 27(8):1529–1540, 2010.
- [20] Qing Yan. *Systems Biology in Drug Discovery and Development*, volume 662 of *Methods in Molecular Biology*. Humana Press, Totowa, NJ, 2010.
- [21] Michael T. Fitch and Jerry Silver. CNS injury, glial scars, and inflammation: Inhibitory extracellular matrices and regeneration failure. *Experimental Neurology*, 209(2):294–301, 2008.
- [22] James a. Dowell, Jeffrey a. Johnson, and Lingjun Li. Identification of astrocyte secreted proteins with a combination of shotgun proteomics and bioinformatics. *Journal of Proteome Research*, 8(8):4135–4143, 2009.
- [23] Anna V. Molofsk, Robert Krenick, Erik Ullian, Hui Hsin Tsai, Benjamin Deneen, William D. Richardson, Ben. Barres, and David H. Rowitch. Astrocytes and disease: A neurodevelopmental perspective. *Genes and Development*, 26:891–907, 2012.

-
- [24] Marta Sidoryk-Wegrzynowicz and Michael Aschner. Role of astrocytes in manganese mediated neurotoxicity. *BMC pharmacology & toxicology*, 14:23, 2013.
- [25] Sunita Gupta, Alecia G. Knight, Shruti Gupta, Jeffrey N. Keller, and Annadora J. Bruce-Keller. Saturated long-chain fatty acids activate inflammatory signaling in astrocytes. *Journal of Neurochemistry*, 120(6):1060–1071, 2012.
- [26] Sudarshana Purkayastha and Dongsheng Cai. Neuroinflammatory basis of metabolic syndrome. *Molecular Metabolism*, 2(4):356–363, 2015.
- [27] Kyoungcho Suk. Proteomics-based discovery of biomarkers and therapeutic targets in neurodegenerative diseases: perspective of microglia and neuroinflammation. *Expert Opinion on Therapeutic Patents*, 16(3):237–247, mar 2006.
- [28] Yoram Vodovotz. Translational systems biology of inflammation and healing. *Wound Repair and Regeneration*, 18(1):3–7, 2010.
- [29] Yoram Vodovotz, Yoram Vodovotz, Marie Csete, Marie Csete, John Bartels, John Bartels, Steven Chang, Steven Chang, Gary An, and Gary An. Translational Systems Biology of Inflammation. *PLoS Comput Biol*, 4(4), 2008.
- [30] Gary An, John Bartels, and Yoram Vodovotz. In silico augmentation of the drug development pipeline: Examples from the study of acute inflammation. *Drug Development Research*, 72(2):187–200, 2011.
- [31] Qi Mi, Nicole Yee-Key Li, Cordelia Ziraldo, Ali Ghuma, Maxim Mikheev, Robert Squires, David O Okonkwo, Katherine Verdolini-Abbott, Gregory Constantine, Gary An, and Yoram Vodovotz. Translational systems biology of inflammation: potential applications to personalized medicine. *Personalized Medicine*, 7(5):549–559, 2010.
- [32] Durgaprasad Laveti, Manoj Kumar, R Hemalatha, Ramakrishna Sistla, V G M Naidu, Venu Talla, Vinod Verma, Navrinder Kaur, and Ravinder Nagpal. Anti-inflammatory treatments for chronic diseases: a review. *Inflammation & allergy drug targets*, 12(5):349–61, 2013.
- [33] Paola Albertazzi, Raffaele Di Micco, and Ettore Zanardi. Tibolone: A review, 1998.
- [34] Katarzyna Wojtal, Michał K. Trojnar, and Stanisław J. Czuczwar. Endogenous neuroprotective factors: Neurosteroids, 2006.
- [35] H. J. Kloosterboer. Tibolone: A steroid with a tissue-specific mode of action. In *Journal of Steroid Biochemistry and Molecular Biology*, volume 76, pages 231–238, 2001.
- [36] Sudhaa Sharma, Annil Mahajan, Sudesh Kumar, and Vishal R. Tandon. Tibolone: A selective tissue estrogenic activity regulator, 2006.

-
- [37] Cees J. Timmer, H. A M Verheul, and D. P. Doorstam. Pharmacokinetics of tibolone in early and late postmenopausal women. *British Journal of Clinical Pharmacology*, 54(2):101–106, 2002.
- [38] M A Altinoz, S B Albayrak, A Karasu, P A Sabanci, M Imer, and A Bilir. The effects of tibolone on the human primary glioblastoma multiforme cell culture and the rat C6 glioma model. *Neurol Res*, 31(9):923–927, 2009.
- [39] Helenius J. Kloosterboer. Tissue-selectivity: the mechanism of action of tibolone. *Maturitas*, 48(SUPPL. 1):30–40, aug 2004.
- [40] Ron Edgar, Michael Domrachev, and Alex E Lash. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. *Nucleic Acids Res*, 30(1):207–210, 2002.
- [41] Ye Zhang, Steven A. Sloan, Laura E. Clarke, Christine Caneda, Colton A. Plaza, Paul D. Blumenthal, Hannes Vogel, Gary K. Steinberg, Michael S B Edwards, Gordon Li, John A. Duncan, Samuel H. Cheshier, Lawrence M. Shuer, Edward F. Chang, Gerald A. Grant, Melanie G Hayden Gephart, and Ben A. Barres. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. *Neuron*, 89(1):37–53, 2016.
- [42] Michael Rebhan, Vered Chalifa-Caspi, Jaime Prilusky, and Doron Lancet. GeneCards: integrating information about genes, proteins and diseases. *Trends in Genetics*, 13(4):163, 1997.
- [43] Donna Maglott, Jim Ostell, Kim D Pruitt, and Tatiana Tatusova. Entrez Gene: gene-centered information at NCBI. *Nucleic acids research*, 33(suppl 1):D54—D58, 2005.
- [44] Marc Carlson. *UniProt.ws: R Interface to UniProt Web Services*, 2016.
- [45] Ines Thiele, Neil Swainston, Ronan M T Fleming, Andreas Hoppe, Swagatika Sahoo, Maike K Aurich, Hulda Haraldsdottir, Monica L Mo, Ottar Rolfsson, Miranda D Stobbe, and Others. A community-driven global reconstruction of human metabolism. *Nature biotechnology*, 31(5):419–425, 2013.
- [46] Kelly Botero, Daniel Osorio, Janneth Gonzalez, and Andres Pinzon. *g2f: Find and Fill Gaps in Metabolic Networks*, 2016.
- [47] Daniel Osorio, Janneth Gonzalez, and Andres Pinzon. minval: MINimal VALidation for Stoichiometric Reactions, 2016.
- [48] Ines Thiele and Bernhard Ø Palsson. A protocol for generating a high-quality genome-scale metabolic reconstruction. *Nature Protocols*, 5(1):93–121, jan 2010.

-
- [49] Daniel Osorio, Kelly Botero, Janneth Gonzalez, and Andres Pinzon. *exp2flux: Convert Gene EXPression Data to FBA FLUXes*, 2016.
- [50] Gabriel Gelius-dietrich, Abdelmoneim Amer Desouki, Claus Jonathan Fritzemeier, and Martin J Lercher. *sybil – Efficient constraint-based modelling in R*. 2013.
- [51] R Core Team. *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria, 2016.
- [52] Jeffrey D Orth, Ines Thiele, and B O Palsson. What is flux balance analysis? *Nature Biotechnology*, 28(3):245–248, 2010.
- [53] Karthik Raman and Nagasuma Chandra. Flux balance analysis of biological systems: Applications and challenges. *Briefings in Bioinformatics*, 10(4):435–449, 2009.
- [54] M T Fitch and J Silver. Activated macrophages and the blood-brain barrier: inflammation after CNS injury leads to increases in putative inhibitory molecules. *Experimental Neurology*, 148(2):587–603, 1997.
- [55] R. Ciccarelli, P. Ballerini, G. Sabatino, M. P. Rathbone, M. D’Onofrio, F. Caciagli, and P. Di Iorio. Involvement of astrocytes in purine-mediated reparative processes in the brain. *International Journal of Developmental Neuroscience*, 19(4):395–414, 2001.
- [56] Tunahan Cakir, Selma Alsan, Hale Saybaşılı, Ata Akin, and Kutlu O Ulgen. Reconstruction and flux analysis of coupling between metabolic pathways of astrocytes and neurons: application to cerebral hypoxia. *Theoretical biology & medical modelling*, 4(1):48, 2007.
- [57] Mustafa Sertbaş, Kutlu Ülgen, and Tunahan Çakir. Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network. *FEBS Open Bio*, 4:542–553, 2014.
- [58] João V. Sá, Susanne Kleiderman, Catarina Brito, Ursula Sonnewald, Marcel Leist, Ana P. Teixeira, and Paula M. Alves. Quantification of Metabolic Rearrangements During Neural Stem Cells Differentiation into Astrocytes by Metabolic Flux Analysis. *Neurochemical Research*, 2016.
- [59] Arabinda Das, Naren L. Banik, and Swapan K. Ray. Flavonoids activated caspases for apoptosis in human glioblastoma T98G and U87MG cells but not in human normal astrocytes. *Cancer*, 116(1):164–176, 2010.
- [60] Christelle Le Foll and Barry E Levin. Fatty acid-induced astrocyte ketone production and the control of food intake. *American journal of physiology. Regulatory, integrative and comparative physiology*, page ajpregu.001113.2016, 2016.

-
- [61] Li Liu, Rebecca Martin, and Christina Chan. Palmitate-activated astrocytes via serine palmitoyltransferase increase BACE1 in primary neurons by sphingomyelinases. *Neurobiology of Aging*, 34(2):540–550, 2013.
- [62] Rafael Rangel-Aldao. The unfolded protein response, inflammation, oscillators, and disease: a systems biology approach. *Endoplasmic Reticulum Stress in Diseases*, 2(1):30–52, 2015.
- [63] Rachel Williams, Cassandra L. Buchheit, Nancy E J Berman, and Steven M. Levine. Pathogenic implications of iron accumulation in multiple sclerosis. *Journal of Neurochemistry*, 120(1):7–25, 2012.
- [64] V Parpura and P G Haydon. Physiological astrocytic calcium levels stimulate glutamate release to modulate adjacent neurons. *Proc.Natl.Acad.Sci.U.S.A*, 97(0027-8424):8629–8634, 2000.
- [65] Leif Hertz, Ralf Dringen, Arne Schousboe, and Stephen R. Robinson. Astrocytes: Glutamate producers for neurons. *Journal of Neuroscience Research*, 57(4):417–428, 1999.
- [66] Yu-Cun Niu, Ren-Nan Feng, Yan Hou, Kang Li, Zhen Kang, Jian Wang, Chang-Hao Sun, and Ying Li. Histidine and arginine are associated with inflammation and oxidative stress in obese women. *British Journal of Nutrition*, 108(01):57–61, 2012.
- [67] Yuan Ti Lee, Cheng Chin Hsu, Meng Hsiao Lin, Keh Sen Liu, and Mei Chin Yin. Histidine and carnosine delay diabetic deterioration in mice and protect human low density lipoprotein against oxidation and glycation. *European Journal of Pharmacology*, 513(1-2):145–150, 2005.
- [68] Dong Ok Son, Hideo Satsu, and Makoto Shimizu. Histidine inhibits oxidative stress- and TNF- α -induced interleukin-8 secretion in intestinal epithelial cells. *FEBS Letters*, 579(21):4671–4677, 2005.
- [69] Morris H Baslow. N -Acetylaspartate in the Vertebrate Brain : Metabolism and Function. 28(6):941–953, 2003.
- [70] Leonard T. Rael, Gregory W. Thomas, Raphael Bar-Or, Michael L. Craun, and David Bar-Or. An anti-inflammatory role for N-acetyl aspartate in stimulated human astroglial cells. *Biochemical and Biophysical Research Communications*, 319(3):847–853, 2004.